Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Layered unitary dosage forms

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

424464000 - Tablets, lozenges, or pills

424468000 - Sustained or differential release type

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424473000 With porous, perforated, apertured, or sieved layer (e.g., dialyzing layer, microporous layer, etc.) 7
Entries
DocumentTitleDate
20120201889MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.08-09-2012
20090123541Pharmaceutical Composition - The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: 05-14-2009
20080260825Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.10-23-2008
20100086592MODIFIED DOSAGE FORMS OF TACROLIMUS - The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described.04-08-2010
20100104639BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.04-29-2010
20100040681Oral Sustained-Release Triple Layer Tablet - The present invention relates to an oral sustained-release triple layer tablet, more particularly, a triple layer tablet consisting of an inner immediate-release layer containing a pharmaceutically active ingredient and two outer layers containing swellable polymers. Upon exposure to aqueous media, the two outer layers swell to form gelled layers surrounding the lateral side of the inner layer rapidly, thereby control effectively the release of the pharmaceutically active ingredient from the inner immediate-release layer.02-18-2010
20090130208Modified release niacin formulations - Modified release niacin formulations, methods for making the formulations, and methods of using the formulations.05-21-2009
20100143470CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS - Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.06-10-2010
20130034605EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PALIPERIDONE - An extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients and process for preparing the same. The present invention particularly relates to an extended release pharmaceutical composition comprising Paliperidone or pharmaceutically acceptable salts thereof and one or more pharmaceutical excipients wherein the core is coated with multiple coatings.02-07-2013
20120164221COMBINATIONS OF HMG-COA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT - The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy, or rhabdomyolysis.06-28-2012
20130089609CONTROLLED RELEASE NUCLEATED TABLET - Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer.04-11-2013
20090317465COMPOSITION AND METHOD OF PREPARATION OF RELEASE SYSTEMS FOR CONSTANT (ZERO-ORDER) RELEASE OF ACTIVE AGENTS - The present invention includes methods and compositions for pharmaceutical compositions that exhibit substantially constant release profile. The composition includes at least two layers with different drug to polymer ratios. The layers can be arranged in any order to achieve desirable pharmaceutical effects.12-24-2009
20090269402MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE - The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.10-29-2009
20090280174Solid Pharmaceutical Preparation - It is intended to provide a long-acting solid pharmaceutical preparation which has an immediate release part and a sustained release part containing tramadol or a pharmaceutically acceptable salt thereof, is fast-acting and stably has an excellent release property showing little pH dependency in the initial elution. The invention relates to a long-acting solid pharmaceutical preparation characterized by having an immediate release part and a sustained release part, containing tramadol or a pharmaceutically acceptable salt thereof as an active ingredient in both parts and containing partially pregelatinized starch and an excipient as additives in the immediate release part. The preparation of the invention is a long-acting preparation in which an effective blood concentration is reached rapidly after taking it for rapid pain-relief and a drug action can be sustained for a long time thereafter and is practical as a preparation showing a stable, pH-independent and rapid initial elution behavior and, further, having a sufficient hardness enough to meet the need for avoidance of defacement, cracking, chipping, etc. during tablet coating.11-12-2009
20090317464METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS - The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition.12-24-2009
20090011019PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY - A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.01-08-2009
20090011018Sustained release formulation for tacrolimus - A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed.01-08-2009
20100003320HYDROPHILIC/LIPOPHILIC POLYMERIC MATRIX DOSAGE FORMULATION - An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.01-07-2010
20080274181BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.11-06-2008
20080292702Solid Dispersion Comprising An Active Ingredient Having A Low Melting Point And Tablet For Oral Administration Comprising Same - A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 mVg can be conveniently compressed into a tablet without generating capping and sticking problems, and a tablet comprising said fused solid dispersion can maintain an uniform release rate over a prolonged time when orally administered.11-27-2008
20090068264Clinical Applications of Tetrahydrobiopterin, Lipoic Acid and Their Salts and Methods of Preparing Tetrahydrobiopterin Bis-Lipoate - Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL). The invention is useful for the amelioration of diabetes mellitus types 1 and 2 (including impaired glucose tolerance, pre-diabetes, insulin resistance, metabolic syndrome X and as an adjunct to oral antidiabetic agents and/or insulin), diabetic and non-diabetic microvascular diseases (including nephropathy, neuropathy and retinopathy), diabetic and non-diabetic macrovascular diseases (including heart attack, stroke, peripheral vascular disease and ischemia-reperfusion injury), hypertension, vasoconstriction, obesity, dyslipedemia, and neurodegenerative disorders (including Parkinson's disease, mild cognitive impairment, senile dementia, Alzheimer's disease, hearing loss and chronic glaucomas). A novel method for the preparation of TBL is also disclosed.03-12-2009
20100247647SUSTAINED RELEASE TABLETS WITH HYDROMORPHONE - The invention relates to a tablet having a tablet core comprising a plurality of active ingredient-containing pellets and one or more pharmaceutically tolerated excipients and at least one coating applied to the tablet core, the active ingredient-containing pellets containing hydromorphone or a salt or a solvate thereof as active ingredient and having the following structure: 09-30-2010
20090022798FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS - The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.01-22-2009
20100255095PHARMACEUTICAL COMPOSITIONS OF FENOFIBRATE - The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.10-07-2010
20100112053GASTRIC RETENTION-TYPE SUSTAINED-RELEASE LEVODOPA PREPARATION - The present invention is to provide a levodopa preparation which is able to persistently release levodopa in the stomach, has a sufficient gastric residence time, is in an easily ingestible size and is able to be easily manufactured industrially with an object of maintaining a sustained concentration of levodopa in blood. It is a gastric retentive preparation for levodopa, characterized in that, the preparation contains a gastric resident layer showing a sufficient retentive property due to a high mechanical strength in the stomach and showing a good disintegrating property in an intestinal tract in addition to a drug releasing layer containing levodopa.05-06-2010
20090148525PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain potassium ATP (K06-11-2009
20120034303PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX - A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).02-09-2012
20100098757PROCESS FOR PRODUCTION OF BUPRENORPHINE PHARMACEUTICAL PREPARATION TO BE APPLIED TO MOUTH MUCOSA - The objective of the present invention is to provide a process for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa. The process according to the present invention for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa includes steps of: preparing a granule for an immediate-release layer containing a buprenorphine hydrochloride crystal having 90% cumulative diameter of 200 μm or less; preparing a granule for a sustained-release layer containing a buprenorphine hydrochloride crystal having 90% cumulative diameter of 250 μm or less; and tabletting the granule for the immediate-release layer and the granule for the sustained-release layer into a two-layer tablet.04-22-2010
20090087488GALANTAMINE-CONTAINING CONTROLLED RELEASE ORAL DOSAGE FORMS, PROCESSES FOR THE PREPARATION THEREOF AND USE OF THE MANUFACTURE OF A MEDICAMENT - The present invention relates to controlled release oral dosage forms of galantamine or acceptable salts thereof and processes for the preparation thereof.04-02-2009
20090263481LEVETIRACETAM FORMULATIONS - Pharmaceutical formulations comprising levetiracetam and having an inner solid phase and outer continuous phase, wherein one or both of the phases comprise at least one hydrophobic material, lipophilic material, or combination thereof.10-22-2009
20100098758Abuse-Resistant Dosage Form - A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least one sub-unit (a), and the at least one emetic is present in the form of at least one sub-unit (b), and the emetic from sub-unit (b) is not activated in the body if the dosage form has been correctly administered as prescribed.04-22-2010
20090297600NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND AN ANGIOTENSIN ANTAGONIST - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.12-03-2009
20100221335SUSTAINED-RELEASE PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a preparation which is a sustained-release preparation capable of providing a dissolution profile that permits once-daily administration even in the case of a highly water-soluble drug, and which can exhibit stable drug dissolution behavior and can be reduced in its size; and a method for producing the same. A preparation containing a highly water-soluble drug, a gel-forming polymer, and a low-melting lipophilic substance is usable as a sustained-release preparation that permits once-daily administration, and enables reduction in its size and simple production thereof, and thus, the objects have been achieved.09-02-2010
20080241241MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.10-02-2008
20080206335MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS - A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration comprises particles of said SSRI or a pharmaceutically acceptable salt thereof coated with rate-controlling polymer which allows controlled release of said SSRI, over a period of not less than about 12 hours following oral administration. The formulation, which contains for example fluvoxamine or a pharmaceutically acceptable salt thereof, is suitable for once or twice daily administration. The formulation can comprise a blend of two or more populations of particles, pellets or mini-tablets having different in vitro and/or in vivo release characteristics.08-28-2008
20100143469PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.06-10-2010
20080268047Controlled Release Multiple Layer Coatings - A process for making controlled release pharmaceutical formulations is provided, which comprises supplying a plurality of solutions with syringe pumps for fluid bed coating, coating a substrate with a pH dependent soluble polymer solution, coating the polymer coated substrate with at least one layer of a solution of a therapeutically active substance and at least one layer of a second polymer solution, and alternating the layers so that the number, order, and volume of the layers controls the release of the therapeutically active substance. In alternate embodiments, the consecutively applied layers may contain coating materials, active ingredients or a mixture of coating materials and active ingredients; the layers can be applied in varying order. Also provided is a system for applying the coatings, wherein the syringe pumps are controlled by a computer in accordance with predetermined instructions.10-30-2008
20080268046Formulations with Controlled Release of Active Ingredient - The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable salts, hydrates, solvates and/or polymorphic forms thereof as active ingredient, and to the production thereof. The invention further relates to the use of these novel pharmaceutical dosage forms as medicaments, and to their use for producing medicaments for the treatment and/or prevention of disorders in humans and animals.10-30-2008
20100143471NOVEL REDUCED DOSE PHARMACEUTICAL COMPOSITIONS OF FEXOFENADINE AND PSEUDOEPHEDRINE - A novel reduced dose pharmaceutical composition comprising combination of fexofenadine or salts thereof; and pseudoephedrine or salts thereof in therapeutically effective amount, for the treatment of allergic rhinitis and associated symptoms in pediatric population.06-10-2010
20090028942Sustained release compositions of alfuzosin - The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers.01-29-2009
20090162434MESALAZINE TABLET - Disclosed are mesalazine tablets and a method for their preparation. The mesalazine tablets comprise a tablet core, a first coating layer, and a second coating layer. The tablet core comprises mesalazine; the first coating layer comprises a cellulose derivative and/or povidone, and the second coating layer comprises methacrylic acid/methyl methacrylate copolymer and an anti-tack agent. The tablets show a high degree of uniformity and reproducibility and release mesalazine starting at pH 6.8 and are used in the treatment of colorectal diseases.06-25-2009
20090186082METHOD OF MANUFACTURING MODIFIED RELEASE DOSAGE FORMS - In one embodiment, a dosage form comprises: (a) at least one active ingredient; (b) a molded core which is solid at room temperature; and (c) a shell which is in contact with at least a portion of the core, wherein the dosage form provides modified release of the active ingredient upon contacting of the dosage form with a liquid medium. In another embodiment of this invention, a dosage form comprises: (a) at least one active ingredient; (b) a molded core comprising a plurality of particles; and (c) a shell which is in contact with at least a portion of the core, wherein the dosage form provides modified release of the active ingredient upon contacting of the dosage form with a liquid medium.07-23-2009
20100015224PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY - The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.01-21-2010
20100260842PSEUDOEPHEDRINE PHARMACEUTICAL FORMULATIONS - Controlled-release pharmaceutical formulations comprising pseudoephedrine or any of its pharmaceutically acceptable salts, processes for preparing the pharmaceutical formulations, and methods of using the formulations.10-14-2010
20100260841Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions - A method of treating atherosclerosis, dyslipidemias and related conditions is disclosed wherein a therapeutic dose of nicotinic acid, approximately 1 gram, is administered to the patient once daily as a starting dose, and the dose is thereafter raised within a few days or weeks to 2 grams for the duration of therapy. The nicotinic acid may be administered in combination with a selective DP receptor antagonist. The selective DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.10-14-2010
20100151023Time delayed release mechanism for energizing composition and method of use - The present invention is directed to a time-release energizing supplement of the present invention comprising energizing ingredients coated by an enteric coating. The energizing ingredients comprise guarana seed extract, eleuthero root extract, tyrosine, and high amounts of B-complex vitamins. The B-complex vitamins preferably comprise thiamin, riboflavin, niacin, vitamin B6, and vitamin B12. The enteric coating of the time-release energizing supplement controls the release of the energizing ingredients inside the user's body and energizes the user by enhancing physical and metal performance over an extended period of time.06-17-2010
20100151022Controlled-release compositions - A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone. 06-17-2010
20090258067MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE - The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.10-15-2009
20130142874PHARMACEUTICAL COMPOSITIONS BASED ON DICLOFENAC - New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher C06-06-2013
20110111027IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE - The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.05-12-2011
20100330179Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.12-30-2010
20110008431THERAPEUTIC TABLET FOR POSTHERPETIC NEURALGIA AND METHOD OF TREATING POSTHERPETIC NEURALGIA - The present invention provides a tablet for treating postherpetic neuralgia and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic neuralgia according to the present invention is characterized in comprising buprenorphine hydrochloride, having a double layer structure consisting of a quick-release layer and a sustained-release layer, wherein the tablet is adhesive to the oral mucosa.01-13-2011
20110008432Method for Treating a Patient in Need of Aspirin Therapy - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.01-13-2011
20090035374METHOD OF MAKING A SINGLE-STAGE PHARMACEUTICAL PREPARATION FOR ORAL THERAPY TO REGULATE BLOOD PRESSURE AND KIT CONTAINING SAME - The single-stage oral contraceptive preparation contains at least 21 daily dosage units, which each contain a contraceptive combination of 2.0 mg of dienogest (not an aidosterone antognist) and 0.030 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.015 mg of ethinyl estradiol, or of 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with one or more pharmaceutically acceptable excipients and/or carriers, and at the most 7 daily dosage units containing a placebo or no active ingredients. The contraceptive preparation also regulates the blood pressure, raising low blood pressure and lowering mildly elevated blood pressure, during its administration for contraception. It is especially suitable for long-duration use as a contraceptive preparation without risk of negatively influencing the blood pressure.02-05-2009
20100172985Tablet Containing Cetirizine, Pseudoephedrine, and Naproxen Containing a Barrier Layer - In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer.07-08-2010
20100172984 TABLET DOSAGE FORM COMPRISING CETIRIZINE AND PSEUDOEPHEDRINE - The present invention relates to a tablet dosage form comprising an immediate release component comprising cetirizine and an extended release component comprising pseudoephedrine.07-08-2010
20090035373PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND BLOOD PRESSURE REGULATION, KIT FOR CONTRACEPTION CONTAINING SAME AND METHOD OF PRODUCTION OF SAME - The pharmaceutical composition for contraception and regulating blood pressure includes daily dosage units, which contain 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, or 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with at least one excipient and/or carrier. Each daily dosage unit may be a coated tablet for oral administration consisting of a tablet core and a coating around the core. The coating contains all of the ethinyl estradiol and a part of the dienogest, which are released in a non-retarded fashion. The tablet core contains another part of the dienogest that is released in a retarded fashion. The risk of folate deficiency-induced congenital malformations in the event of pregnancy may be reduced by including (6S)-5-methyltetrahydrofolate in each daily dosage unit. A kit for a 28-day cycle is also disclosed.02-05-2009
20110177167Hydrophilic/Lipophilic Polymeric Matrix Dosage Formulation - An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.07-21-2011
20110064808EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.03-17-2011
20120201888Pharmaceutical Compositions - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.08-09-2012
20120201887Pharmaceutical Formulation - A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein said first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.08-09-2012
20110212175COMBINATION PREPARATION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKER AND HMG-COA REDUCTASE INHIBITOR - Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.09-01-2011
20110177168COMPOSITION - A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.07-21-2011
20110165239PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN - The present invention provides stable pharmaceutical compositions comprised of atorvastatin and sodium bicarbonate or L-arginine. The compositions are prepared as bulk drug compositions and also as oral dosage units, such as tablets or capsules. The compositions are useful for preparation of monolithic and bi-layer tablets containing atorvastatin as the only active agent or combined with one or more additional active agents. The compositions are useful for treating hypercholesterolemia and related conditions.07-07-2011
20110052689SUSTAINED RELEASE OF GUAIFENESIN - The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1: 1) to about nine-to-one (9: 1), more preferably a range of about three-to-two (3:2) to about six-to-one (6: 1), and most preferably in a range of about two-to-one (2: 1) to about four-to-one (4: 1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.03-03-2011
20110052688SOLID DISPERSION COMPOSITION - A solid dispersion extended release tablet composition is provided. The composition comprises fluvastatin sodium and a polymer, wherein molecules of the fluvastatin sodium are separate from one another and dispersed in the polymer, and wherein the composition displays two distinct peaks at about 3.5 and 20.4.degrees 2θ of X-ray diffraction.03-03-2011
20110052687EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF PALIPERIDONE - The present invention provides an extended release tablet of paliperidone, comprising a) a core containing paliperidone and at least one water soluble and/or gellable polymer, b) a coating comprising at least one water insoluble or permeable polymer, and a water soluble and/or gellable polymer and optionally an enteric polymer.03-03-2011
20110097400MAGNESIUM SYSTEM AND USE THEREOF IN THE COSMETICS INDUSTRY - A magnesium-based system suitable for use in skincare comprises (a) a first magnesium source in the form of a progressive-release oral tablet exhibiting in vitro, after 2 h in 0.1N HCl medium, a rate of dissolution (δ) of the magnesium contained therein of less than or equal to 60% by weight relative to the total weight of the Mg provided by the first magnesium source, and (b) a second magnesium source in a topical preparation. A method for treating skin for stress, fatigue or skin barrier deficiencies, as well as for stratum corneum hydration, includes orally and topically administering magnesium sources (a) and (b), respectively.04-28-2011
20100159004METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.06-24-2010
20090175939PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.07-09-2009
20090175938Controlled Release Flurbiprofen and Muscle Relaxant Combinations - This invention is a novel controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration with anti-inflammatory, analgesic, myorelaxant activity and methods of its manufacture. The pharmaceutical composition of the present invention is administered orally in tablet, multilayer tablet, multicoated tablet and capsule form.07-09-2009
20100021542EXTENDED RELEASE ORAL DOSAGE COMPOSITION - A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.01-28-2010
20100092556ALFUZOSIN FORMULATIONS, METHODS OF MAKING, AND METHODS OF USE - Alfuzosin compositions comprising a tablet core of alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, based on the total weight of the tablet core; and an extended-release coating substantially surrounding the tablet core comprising a release-retarding coating material, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 (UROXATRAL) are disclosed. Methods of making and using the alfuzosin compositions are also disclosed.04-15-2010
20090208572ORAL CONTROLLED RELEASE TABLET - A method of reducing the risk of alcohol-induced dose-dumping of a therapeutically active ingredient comprising administering to human subjects who have ingested alcohol an oral controlled release tablet; said tablet comprising: 08-20-2009
20090280175Multilayer Proton Pump Inhibitor Tablets - Multilayer tablets of a proton pump inhibitor essentially bioequivalent in terms of plasma C11-12-2009
20090280176CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM - A controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile, is provided.11-12-2009
20100178341BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR - The present invention relates to a bilayered tablet comprising: a slow release layer comprising niacin and release retarding agent; and an immediate release layer comprising HMG-CoA reductase inhibitor.07-15-2010
20090104264CONTROLLED RELEASE SOLID PREPARATION - The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing a combination of (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a basic substance, and having a film that dissolves at pH 6.5 or above.04-23-2009
20100112054TABLETS AND DISCS WITH COMPARTMENTS WITH TWO OR MORE DRUGS FOR RELEASE AT CERTAIN INTERVALS AND WITH SPECIFIC RATES - The present invention includes systems, compositions and methods of making a multilayer modular release system, wherein the layers form a stack of active agent release layers, wherein the stack comprises a body and first and second ends and an impermeable coating surrounding the body of the stack, wherein the active agent is only release from the first, second or both the first and second ends of the stack by diffusion.05-06-2010
20100015223Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion - Water-insoluble matrix tablets which are capable of prolonged release of active principles liable to be diverted for drug addiction purposes, the said active principles being dispersed within a tabletting matrix composed of at least one excipient selected from the group consisting of pH-independent, water-insoluble delay polymers, inorganic excipients and mixtures thereof, and exhibiting a crush resistance of at least 4 MPa.01-21-2010
20080311201MODIFIED RELEASE SOLID OR SEMI-SOLID DOSAGE FORMS - A solid or semi-solid pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.12-18-2008
20110064807EXTENDED RELEASE FORMULATION OF LEVETIRACETAM - An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.03-17-2011
20120156294Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration - The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above.06-21-2012
20120003312Multilayer Minitablets with Different Release Rates - Multilayer minitablets for oral administration of a combination of active pharmaceutical ingredients which release the active pharmaceutical ingredient at different release rates are described.01-05-2012
20120015031NOVEL GASTRO-RETENTIVE DOSAGE FORMS - A gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, optionally an opioid antagonist and at least one pharmaceutically acceptable excipient, which dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. Also provided is a method of treating pain by administering the dosage form to a patient in need thereof. The acetaminophen is either in slow release form or in immediate release form or as combination of both.01-19-2012
20100092557Dosage Form Comprising Immediate Release Naproxen and Sustained Release Opioid Analgesic - A dosage form adapted for twice-a-day administration comprising a naproxen species in an immediate release phase and an opioid analgesic in a sustained release phase. The dosage form is useful in the treatment of pain.04-15-2010
20090130207Pharmaceutical Tablets Having a Relatively Inactive Segment - An immediate release drug containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.05-21-2009
20090117184Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception - Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17β-estradiol or estradiol valerate, and one or more pharmaceutically acceptable auxiliary agents/excipients provide lactose-free oral contraception.05-07-2009
20120177736METHOD FOR TREATING A PATIENT IN NEED OF ASPIRIN THERAPY - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.07-12-2012
20100008987Modified Release Pharmaceutical Composition of Bupropion Hydrochloride - A delayed extended release pharmaceutical composition includes a compressed core containing an effective amount of bupropion or its pharmaceutically acceptable salt, a water-attractant polymer. The core is preferably devoid of a stabilizer. The core is surrounded by an extended release layer, which is free of plasticizer and pore-forming agent. The extended release layer is surrounded by a delayed release layer. Alternating coats of extended release layer and delayed release layer may follow. A preferred extended release layer includes ethylcellulose and hydroxypropyl cellulose or hydroxypropyl methylcellulose and a preferred delayed release layer includes methacrylic acid copolymer and hydroxypropyl methylcellulose phthalate, lactose and a combination of triethyl citrate and polyethylene glycol and talc. A method of preparing the delayed extended release bupropion hydrochloride containing pharmaceutical composition is also disclosed.01-14-2010
20120258173Functionally-Coated Multilayer Tablets - Multilayer functionally coated tablets for oral administration of one or more active pharmaceutical ingredients containing one or more quick release layers and one or more modified release layers separated by an inert layer are provided. Also provided are methods for formulation and use of these tablets.10-11-2012
20130183383PHARMACEUTICAL COMPOSITIONS FOR CALANOLIDES, THEIR DERIVATIVES AND ANALOGUES, AND PROCESS FOR PRODUCING THE SAME - The present invention relates to pharmaceutical compositions of calanolides, their derivatives and analogues, and process for producing the same having enhanced solubility and bioavailability for oral or parenteral administration. The invention further provides for a method of using the disclosed compositions for the treatment and prevention of retroviral diseases such as human immunodeficiency, specifically HTV-1 and mycobacterial diseases especially tuberculosis infections in mammals, particularly humans.07-18-2013
20110305756COATED SOLID PREPARATION - A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure.12-15-2011
20110159095TREATMENT OF ADRENAL INSUFFICIENCY - The disclosure relates to a pharmaceutical formulation, for example a tablet, adapted for delayed and sustained release of hydrocortisone and a treatment regime that uses said tablet in the treatment of adrenal insufficiency.06-30-2011
20110159094EXTENDED RELEASE COMPOSITIONS FOR HIGH SOLUBILITY, HIGH PERMEABILITY ACTIVE PHARMACEUTICAL INGREDIENTS - A novel composition comprising a tablet, comprising a highly soluble active pharmaceutical ingredient, which is then coated with a coating. The core is preferably a tablet. The coating preferably comprises any type of suitable extended release polymer, with the proviso that the polymer does not comprise an enteric polymer.06-30-2011
20080254121Multi-layer melatonin composition - A multi-layered solid dosage form for oral administration for a multi-phasic controlled release of Melatonin is described. The solid dosage form is useful as a composition to promote and maintain a state of sleep in an individual.10-16-2008
20080248114ORAL OSMOTIC DRUG DELIVERY SYSTEM - The present invention relates, generally, to oral osmotic drug delivery systems, methods of preparing same, and methods of using oral osmotic drug delivery systems to provide controlled delivery of a drug. The oral osmotic drug delivery systems include a drug layer, an osmotic layer, and an outer coating surrounding the drug layer and osmotic layer, where the outer coating includes at least one opening therein that is provided adjacent the drug layer. The composition (% fines), shape, and weight gain of the oral osmotic delivery systems may be modified in order to provide for optimized release of the drug contained therein.10-09-2008
20110262539PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.10-27-2011
20130115289ANTI-FLUSH COMPOSITIONS - Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin. Methods of using such compositions to treat diseases or conditions suitably treated by niacin are also provided which result in reduced flushing.05-09-2013
20080199522TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION - The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1) drug and freely erodible filler are mixed with the core tablet, (2) the percentage erosion of the core tablet is approximately 40 to approximately 90%, and (3) the outer layer essentially does not contain the same drug as the above-mentioned drug. By releasing a drug after a specific lag time, it becomes possible to effectively deliver a drug to a specific site in the digestive tract. It is therefore useful as presented as a timed-release solid composition for oral administration of a drug that is to be effectively delivered in high concentrations to the afflicted site in the lower digestive tract, a drug that is to be effectively absorbed in the lower digestive tract, a drug that is effective for chronopharmacotherapy, etc.08-21-2008
20130149379GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT - Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.06-13-2013
20120276201COMPOSITIONS AND METHOD FOR TREATMENT AND PROPHYLAXIS OF INFLAMMATORY BOWEL DISEASE - Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD.11-01-2012
20100316712PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration.12-16-2010
20120282338Extended Release Formulation - The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.11-08-2012
20110311627CONTROLLED RELEASE LEVETIRACETAM FORMULATIONS AND METHODS FOR PRODUCING THE SAME - Pharmaceutical compositions in the form of tablets are disclosed including water-soluble active ingredients such as levetiracetam and a polymer component which primarily includes water-insoluble polymers comprising between 60% and 100% of the polymer component in the tablet core, preferably the entire polymer component in the tablet core. The pharmaceutical compositions can also include an extended-release coating including both water-soluble and water-insoluble polymers.12-22-2011

Patent applications in class Layered unitary dosage forms

Patent applications in all subclasses Layered unitary dosage forms